Orlistat vs Mounjaro in Australia

No randomised trial has put orlistat against tirzepatide or semaglutide; a Europe PMC search of randomised controlled trials on 6 October 2026 returned none. The closest orlistat has come to a GLP-1 medicine is a 2009 Lancet trial in which an open-label orlistat arm lost 4.1 kg over 20 weeks against 7.2 kg on liraglutide 3 mg and 2.8 kg on placebo (n=564, Novo Nordisk funded). Everything else is indirect: each drug's placebo-controlled trials, or a network meta-analysis that pools them.

The two largest placebo-controlled trials, side by side. Different populations, durations and statistical methods, so the figures are not a comparison.

One works in the gut and the other on hormone receptors, so the two share almost no side effects. Figures are from the Australian Product Information for each: for orlistat, the Orlistat Viatris document (a generic of Xenical, reporting the Xenical trial data); for Mounjaro, the Eli Lilly document revised 16 September 2026.

Orlistat: the signature effects are from undigested fat. The Product Information lists oily spotting, flatus with discharge, faecal urgency, fatty or oily stool, flatulence, abdominal pain, oily evacuation, liquid stools, more frequent bowel motions and faecal incontinence as "commonly or very commonly observed". They are worse after high-fat meals, mostly occur within the first three months, and most people have only one episode. In year one of the controlled trials 8.8% stopped for side effects against 4.9% on placebo. The Australian document gives categories, not percentages; the US label, from the same seven trials, puts oily spotting at 26.6% vs 1.3%, faecal urgency at 22.1% vs 6.7% and faecal incontinence at 7.7% vs 0.9% in year one. Rare post-marketing reports include hypersensitivity, pancreatitis, hepatitis with "exceptional cases of severe liver injury" where "no causal relationship has been established", and oxalate kidney damage.

Mounjaro: nausea, diarrhoea, constipation and vomiting are the common effects and they cluster around each dose increase. In the weight-management trials 24.6% to 29.0% had nausea depending on dose, against 8.5% on placebo; diarrhoea 18.7% to 22.5% vs 7.8%; vomiting 8.3% to 12.5% vs 2.2%; hair loss 4.7% vs 0.8%. In the PI's pooled placebo-controlled trials, a wider pool than the weight-management studies, between 3.0% (5 mg) and 6.6% (15 mg) stopped for a gut side effect, against 0.4% on placebo. Symptoms the Consumer Medicine Information says need urgent attention: severe and persistent stomach or back pain, with or without vomiting (possible pancreatitis); swelling of the face or throat, hives or trouble breathing; loss of vision; sudden severe upper-abdominal pain, fever or yellowing of the skin or eyes (gallbladder). Severe vomiting or diarrhoea can cause dehydration and kidney problems.

Orlistat 120 mg is Schedule 3, a Pharmacist Only Medicine, under the Poisons Standard (June 2026 instrument: "orlistat in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit"). No prescription is required by law; a pharmacist must supply it. The Product Information's criteria are a BMI of 30 or more, or 27 or more with other risk factors, alongside a mildly reduced-energy diet with no more than 30% of calories from fat. Online, Chemist Warehouse requires a phone call with its pharmacist within five business days of ordering or the item is removed; Chemist Outlet requires a call within 48 hours unless you supply a script; Your Discount Chemist will not dispatch without a script, which is that retailer's policy and not the law. Pack sizes are 9, 21, 42 and 84 capsules.

Mounjaro is Schedule 4, prescription-only. A GP, a specialist or a nurse practitioner (within their scope of practice; rules vary by state and territory) can write a private script. The Product Information's starting criteria for weight management are a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnoea, heart disease, prediabetes or type 2 diabetes, alongside a reduced-energy diet and more physical activity. Telehealth programs sell a monthly bundle of consultations, medicine and delivery; the medicine and dose are decided at the consultation. Compounded tirzepatide has been illegal to make or supply since 1 October 2024, and in March 2026 the TGA reported that imported unregistered products labelled as GLP-1 contained none.

On weight loss the indirect evidence points one way. Tirzepatide 15 mg produced 20.9% average loss over 72 weeks in SURMOUNT-1. Orlistat's best result, XENDOS year one, was 4.4 kg more than placebo; later meta-analyses put its effect at 2.6 to 2.9 kg, and the 2026 BMJ network meta-analysis did not find it convincingly different from lifestyle change alone, while finding tirzepatide and CagriSema (a combination still under regulatory review) the most effective of the 19 drugs it compared. Orlistat wins on price (about $95 against $390 to $690 a month), on access (no script, no consultation) and on the length of its safety record (registered since 2000, four-year trial data). The April 2025 AJGP review says orlistat "can be considered in patients with cardiovascular disease or hypertension where incretin-based therapies are not tolerated or unaffordable", and puts incretin medicines such as Mounjaro first line where type 2 diabetes, cardiovascular disease, sleep apnoea or fatty liver disease is present.

No Australian guidance covers moving from orlistat to Mounjaro or back, and neither Product Information mentions the other medicine. The orlistat document says that "in the absence of interaction studies, the concomitant administration with other anti-obesity agents is not recommended"; the Mounjaro document is silent on combining. No trial has tested the two together. The one Australian source that positions them, the April 2025 AJGP review, treats orlistat as the fallback where incretin medicines are not tolerated or cannot be afforded, and says to stop a drug and try another if less than 5% of body weight has been lost after 12 weeks at the maximum dose.

There is no dose to convert. Orlistat has one dose, 120 mg with each main meal; the document says higher doses add no benefit. Mounjaro starts at 2.5 mg weekly for four weeks, then 5 mg, with increases of 2.5 mg after at least four weeks on a dose, to a maximum of 15 mg; maintenance doses are 5, 10 and 15 mg. The Product Information gives one starting dose, 2.5 mg, so someone moving to Mounjaro starts the escalation from the beginning.

Weight regain after stopping is documented for both. In SURMOUNT-4, people switched from tirzepatide to placebo after 36 weeks regained 14.0% of their body weight over the next year while those who continued lost a further 5.5%. For orlistat, the Cochrane update found that in the four trials with a second maintenance year both groups regained similar amounts and the difference between them was preserved; the Australian document says "possible weight regain and/or attenuation of weight loss may occur after 1 year". Australian Prescriber's 2025 review of injectables: "when treatment is stopped, regaining weight is the norm".